Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate
Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate
复制标题
DOI：
10.1038/pcan.2009.41
复制
发表时间：
2010-03-01
影响因子：
4.8
通讯作者：
Kuehn, R.
中科院分区：
文献类型：
--
作者：
Labanaris, A. P.;Engelhard, K.;Kuehn, R.
这项研究的目的是报告我们的方法，使用18核经直肠超声(TRUS)前列腺活检(PB)方案，结合常规(e-CMRI)和功能性(e-fMRI)前列腺直肠内磁共振成像(e-MRI)中可疑图像的额外靶点。从2004年到2008年，连续260名临床怀疑前列腺癌的患者接受了PB，并进行了前瞻性研究。所有患者在PB前均行e-cMRI和e-fMRI检查。根据放射学检查结果将患者分为A组和B组(A组=可疑发现，B组=非可疑发现)。图像处理完成后，在18核TRUS引导下进行经皮穿刺术。当一名患者在e-CMRI和e-fMRI图像上显示可疑部位时，从该部位获得另外三个靶向PB。在A组中，18核PB检测到17.5%的PCa，靶点检测到56.5%的PCa。总的PCA检测率(18个以上靶点)为73.9%。总的特异性为73.9%。B组总的假阳性率达19.2%，总的敏感度为80.8%。该方法不仅实用，而且是一种很有前途的主成分分析检测方法。如图所示，当将18核和目标核PB模式组合在一起时，PCA被最佳检测。不可疑的图像不排除PCA的可能性，因此也证明了这些患者存在PB。前列腺癌和前列腺癌(2010年)13，65-70；DOI：10.1038/pcan.2009.41；2009年9月15日在线发布
purpose of this study is to report our method in detecting prostate cancer (PCa) using an 18-core transrectal ultrasound (TRUS) prostate biopsy (PB) schema, in combination with additional targeted cores from suspicious images in conventional (e-cMRI) and functional (e-fMRI) endorectal magnetic resonance imaging (e-MRI) of the prostate. From 2004 to 2008, 260 consecutive patients with a clinical suspicion of PCa underwent PB and were prospectively studied. e-cMRI and e-fMRI was performed in all patients before PB. The patients were divided into two groups (A and B) according to the results of their radiological findings (group A=suspicious findings, group B=non-suspicious findings). After the images were processed, an 18-core TRUS-guided PB was performed. When a patient exhibited a suspicious site on e-cMRI and e-fMRI images, three additional targeted PBs were obtained from that site. In group A, 17.5% of PCa was detected by the 18-core PB and 56.5% of PCa was detected by the targeted cores. The overall PCa detection rate (18+targeted cores) was 73.9%. The overall specificity was 73.9%. In group B, overall false-positive detection rate reached 19.2%, with the overall sensitivity being 80.8%. The method described above is not only practical but also a promising modality in PCa detection. As seen, PCa was optimally detected when combining the 18-core and targeted-core PB schema together. Non-suspicious images do not rule out the probability of PCa, thus justifying a PB in these patients as well. Prostate Cancer and Prostatic Diseases (2010) 13, 65-70; doi:10.1038/pcan.2009.41; published online 15 September 2009